Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials

Autor: Sakai, Soichi, Kaku, Kohei, Seino, Yutaka, Inagaki, Nobuya, Haneda, Masakazu, Sasaki, Takashi, Fukatsu, Atsushi, Kakiuchi, Haruka, Samukawa, Yoshishige
Zdroj: In Clinical Therapeutics April 2016 38(4):843-862
Databáze: ScienceDirect
Externí odkaz: